Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
相关临床试验
20
18 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
16
80.0%
尚未招募
2
10.0%
终止
2
10.0%
暂无批准数据
- The global pulmonary arterial hypertension pipeline comprises over 55 companies developing 55+ therapeutic candidates across all clinical phases, representing significant industry investment in this rare disease. - Merck's WINREVAIR (sotatercept-csrk) demonstrated a 76% reduction in relative risk of major morbidity and mortality events in high-risk PAH patients during Phase 3 ZENITH trial results. - Recent regulatory milestones include FDA Fast Track designation for Cereno Scientific's CS1 and IND clearance for VASTHERA's VTB-10, highlighting accelerated development pathways for novel PAH therapies. - AllRock Bio secured $50 million in Series A funding to advance ROC-101, a first-in-class pan-ROCK inhibitor, into Phase 2 trials for PAH and pulmonary hypertension associated with interstitial lung disease.
- Jade Biosciences completed a reverse merger and raised approximately $300 million, providing financial runway through 2027 to advance its autoimmune disease pipeline. - The company's lead candidate JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy, is expected to enter first-in-human clinical trials in the second half of 2025. - JADE101 targets the APRIL protein to reduce disease-driving IgA levels and preserve kidney function, with engineered half-life extension technology allowing dosing intervals of at least eight weeks. - The company also nominated JADE201 as a development candidate from its JADE-002 antibody discovery program, expanding its preclinical pipeline for autoimmune diseases.
• Major pharmaceutical companies including Pfizer, Novartis, and Takeda have implemented significant workforce reductions over the past year due to patent cliffs and economic pressures. • Unlike previous trends, current layoffs are heavily impacting R&D departments, marking a shift from traditional commercial-focused cuts and reflecting the industry's evolving outsourcing landscape. • Contract Research Organizations (CROs) are benefiting from the industry shift, absorbing displaced talent and gaining additional business as pharmaceutical companies restructure their operations.
